Thirty-Day Mortality of Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia: Insights from a Retrospective Cohort Study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Although glycopeptides remain the preferred treatment for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, the treatment of persistent MRSA bacteremia has been challenging. We investigated real-world treatment strategies for persistent MRSA bacteremia, with a specific emphasis on the use of antimicrobial agents and the frequency of changes during the treatment course. We retrospectively identified patients with persistent MRSA bacteremia in four university-affiliated hospitals between 2017 and 2021. The primary objective of this study was to investigate the patterns of antimicrobial uses for MRSA bacteremia. The secondary objectives were evaluating the associated factors with 1) overall 30-day mortality and 2) changing agents during the treatment course. Time-dependent Cox regression analysis was used to adjust for immortal time bias. Among 116 patients, 37.1% underwent antimicrobials switching, primarily prompted by persistent bacteremia. The 30-day mortality rates of groups with and without antimicrobial switching were 21.4% and 44.2%, respectively (p=0.010 by log-rank test); however, after adjustment for immortal time bias, there was no statistical significance between the two groups (adjusted hazard ratio 0.24, 95% confidence interval 0.03–2.17, p=0.238). Only the Pitt bacteremia score on day 4 and pneumonia were associated with 30-day mortality. Meanwhile, the factors associated with antimicrobial switching were the duration of bacteremia, the initial use of teicoplanin, echocardiogram, and Charlson comorbidity index. This study showed that while over one-third of persistent MRSA bacteremia patients experience changes in antimicrobial agents during treatment, this practice does not significantly improve the 30-day mortality. Our study suggests the need for more effective treatment strategies in managing persistent MRSA bacteremia.
Abstract
Although glycopeptides remain the preferred treatment for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, the treatment of persistent MRSA bacteremia has been challenging. We investigated real-world treatment strategies for persistent MRSA bacteremia, with a specific emphasis on the use of antimicrobial agents and the frequency of changes during the treatment course. We retrospectively identified patients with persistent MRSA bacteremia in four university-affiliated hospitals between 2017 and 2021. The primary objective of this study was to investigate the patterns of antimicrobial uses for MRSA bacteremia. The secondary objectives were evaluating the associated factors with 1) overall 30-day mortality and 2) changing agents during the treatment course. Time-dependent Cox regression analysis was used to adjust for immortal time bias. Among 116 patients, 37.1% underwent antimicrobials switching, primarily prompted by persistent bacteremia. The 30-day mortality rates of groups with and without antimicrobial switching were 21.4% and 44.2%, respectively (p=0.010 by log-rank test); however, after adjustment for immortal time bias, there was no statistical significance between the two groups (adjusted hazard ratio 0.24, 95% confidence interval 0.03–2.17, p=0.238). Only the Pitt bacteremia score on day 4 and pneumonia were associated with 30-day mortality. Meanwhile, the factors associated with antimicrobial switching were the duration of bacteremia, the initial use of teicoplanin, echocardiogram, and Charlson comorbidity index. This study showed that while over one-third of persistent MRSA bacteremia patients experience changes in antimicrobial agents during treatment, this practice does not significantly improve the 30-day mortality. Our study suggests the need for more effective treatment strategies in managing persistent MRSA bacteremia.
참고문헌 (19)
- Howden BP, "Staphylococcus aureus host interactions and adaptation", Nat Rev Microbiol, 21, pp.380~395 (2023)
- Jevons MP, ""Celbenin"-resistant staphylococci", Br Med J, 1, pp.124~ (1961)
- Choi SH, "A longitudinal study of adult patients with Staphylococcus aureus bacteremia over 11 years in Korea", J Korean Med Sci, 36, pp.e104~ (2021)
- Joo EJ, "Reevaluation of the impact of methicillin-resistance on outcomes in patients with Staphylococcus aureus bacteremia and endocarditis", Korean J Intern Med, 34, pp.1347~1362 (2019)
- Rybak MJ, "Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections : a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists", Am J Health Syst Pharm, 77, pp.835~864 (2020)
- Minter DJ, "Contemporary management of Staphylococcus aureus bacteremia-controversies in clinical practice", Clin Infect Dis, 77, pp.e57~e68 (2023)
- Holland TL, "Persistent methicilin-resistant Staphylococcus aureus bacteremia : resetting the clock for optimal management", Clin Infect Dis, 75, pp.1668~1674 (2022)
- Kim SH, "Factors for mortality in patients with persistent Staphylococcus aureus bacteremia : the importance of treatment response rather than bacteremia duration", J Microbiol Immunol Infect, 56, pp.1007~1015 (2023)
- Kuehl R, "Defining persistent Staphylococcus aureus bacteraemia : secondary analysis of a prospective cohort study", Lancet Infect Dis, 20, pp.1409~1417 (2020)
- Chow JW, "Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia : a commentary", Int J Antimicrob Agents, 11, pp.7~12 (1999)
- Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies : development and validation", J Chronic Dis, 40, pp.373~383 (1987)
- Chung H, "C-reactive protein predicts persistent bacteremia caused by community-acquired methicillin-resistant Staphylococcus aureus strain", Eur J Clin Microbiol Infect Dis, 40, pp.2497~2504 (2021)
- Friedman ND, "Health care–associated bloodstream infections in adults : a reason to change the accepted definition of community-acquired infections", Ann Intern Med, 137, pp.791~797 (2002)
- Bai AD, "Staphylococcus aureus bacteraemia mortality : a systematic review and meta-analysis", Clin Microbiol Infect, 28, pp.1076~1084 (2022)
- "Ministry of Health and Welfare Notice No. 2021-161"[URL]
- McCreary EK, "Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments", Open Forum Infect Dis, 7, pp.ofz538~ (2019)
- Kim SH, "Weightbased vancomycin loading strategy may not improve achievement of optimal vancomycin concentration in patients with preserved renal function", J Chemother, 33, pp.56~61 (2021)
- Choi JS, "Therapeutic drug level monitoring of teicoplanin in Korean pediatric patients with normal versus impaired renal function", J Korean Med Sci, 35, pp.e376~ (2020)
- Kim SH, "Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring : not too high for adverse event, not too low for treatment efficacy", Eur J Clin Microbiol Infect Dis, 38, pp.2113~2120 (2019)